Department of Pharmaceutics, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Changa, Gujarat 388421, India.
Recent Pat Nanotechnol. 2023;17(3):208-227. doi: 10.2174/1872210516666220628150447.
The most common vaginal disorders are within the uterus. According to the latest statistics, vaginal disorders occur in 50% to 60% of females. Although curative treatments rely on surgical therapy, still first-line treatment is a non invasive drug. Conventional therapies are available in the oral and parenteral route, leading to nonspecific targeting, which can cause dose-related side effects. Vaginal disorders are localized uterine disorders in which intrauterine delivery via the vaginal site is deemed the preferable route to mitigate clinical drug delivery limitations.
This study emphasizes the progress of site-specific and controlled delivery of therapeutics in the treatment of vaginal disorders and systemic adverse effects as well as the therapeutic efficacy.
Related research reports and patents associated with topics are collected, utilized, and summarized the key findings.
The comprehensive literature study and patents like (US 9393216 B2), (JP6672370B2), and (WO2018041268A1) indicated that nanocarriers are effective above traditional treatments and have some significant efficacy with novelty.
Nowadays, site-specific and controlled delivery of therapeutics for the treatment of vaginal disorders is essential to prevent systemic adverse effects and therapeutic efficacy would be more effective. Nanocarriers have therefore been used to bypass the problems associated with traditional delivery systems for the vaginal disorder.
最常见的阴道疾病发生在子宫内。根据最新统计，50%至 60%的女性患有阴道疾病。尽管治疗方法主要依赖于手术疗法，但仍将非侵入性药物作为一线治疗方法。常规疗法可通过口服和注射途径给药，但存在非特异性靶向问题，可能导致与剂量相关的副作用。阴道疾病是局部性子宫疾病，通过阴道途径宫内给药被认为是减轻临床药物递送限制的首选方法。
本研究强调了治疗阴道疾病和全身不良反应以及治疗效果的局部和控制递药的进展。
收集、利用并总结了与主题相关的研究报告和专利等相关研究报告和专利。
全面的文献研究和专利（如 US 9393216 B2、JP6672370B2 和 WO2018041268A1）表明，纳米载体在传统治疗方法之上具有疗效，且具有一定的新颖性和显著疗效。
如今，治疗阴道疾病的局部和控制递药对于预防全身不良反应和提高治疗效果至关重要。因此，纳米载体已被用于解决与传统阴道疾病递药系统相关的问题。
